Syngene International Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/d97w9ucvf8d63voo0xvlfx72.pdf

Key Takeaways


Sequential Recovery After a Weak Q1

Biswas: "With improving sequential revenues, our operating EBITDA margin came in at 27% for the quarter compared to 22% in the first quarter and broadly within range year-on-year."

Discovery Services: Early Recovery, China-Plus-One Driver

Hunt: "I am pleased with the early positive signs of recovery in Discovery Services, largely driven by collaborations on pilot projects with large and mid-sized biopharma clients looking for alternatives to China to rebalance their supply chains."

Development & Manufacturing: Biologics Build-Out


Cost Structure: Staff Costs the Pressure Point


Balance Sheet & Capital Position


Leadership Changes


Guidance & Commitments

CommitmentSpecificsTimeline
Full-year revenue guidanceRemain on track to deliver within guidance rangeFY25
Positive revenue trajectoryExpect a positive change in revenue trajectoryQ3 FY25
Unit III biologics facilityCommence operations with single-use bioreactors, development suite and two vial filling linesH2 FY25
Medium-to-long-term growthLeverage recent investments in research and CDMO businessesMedium to long term (undated)

Key Metrics

MetricQ2 FY25
Revenue from operations₹891 cr, down 2% YoY, up 13% QoQ
Revenue from operations (constant currency)down 3% YoY
Reported EBITDA₹261 cr, down 5% YoY
Reported EBITDA margin28.8%, vs 29.6% in Q2 FY24
Operating EBITDA margin27%, vs 22% in Q1 FY25
PAT before exceptional item₹106 cr, down 13% YoY
PAT margin (before exceptional items)11.7%, vs 13.1% in Q2 FY24
PAT after exceptional item₹106 cr, down 9% YoY
H1 FY25 revenue from operations₹1,681 cr, down 2% YoY, broadly flat in line with guidance
H1 FY25 PAT after exceptional item₹182 cr, down 13% YoY
Staff costs₹271 cr, 30.4% of revenue, up 12.5% YoY
Foreign exchange gain/(loss), netgain of ₹4.3 cr, vs loss of ₹17.9 cr in Q2 FY24
Audits in first 6 monthsmore than 60, a 36% increase YoY
Cash and cash equivalents₹220.6 cr as at 30 Sep 2024, vs ₹85.7 cr as at 31 Mar 2024